ACHIEVE LIFE SCIENCES, INC. — Director's Dealing 2012

Feb 7, 2012

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: ONCOGENEX PHARMACEUTICALS, INC. (OGXI)
CIK: 0000949858
Period of Report: 2011-12-31

Reporting Person: Clendeninn Neil James (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2011-05-26	Stock Options (right to buy)	$17.82	A	3500	Acquired	2021-05-26	Common Stock (3500)	Direct

Footnotes

F1: The options vest the earlier of the first anniversary of May 26, 2011 or the date immediately prior to Oncogenex Pharmaceuticals, Inc.'s next annual meeting of stockholders.